BSECompany UpdateResults22 Jul 2026
Lupin Ltd
Schedule of Earnings Call for Q1 FY27
Lupin Ltd has scheduled an earnings call for Q1 FY27 on August 07, 2026, at 16:30 hrs (IST).
Read more →📎 1 attachment
Lupin Ltd
BSE: 500257
24
total announcements
500257.BO · 15 min delayed
BSEBoard MeetingResults22 Jul 2026
Lupin Ltd
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Lupin Ltd has scheduled a Board meeting on August 06, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Read more →📎 1 attachment
BSECompany UpdateM&A21 Jul 2026
Lupin Ltd
Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A.
Lupin Ltd's wholly owned subsidiary, Lupin Inc. U.S.A., has entered into a licensing agreement with Kaveri Therapeutics, Inc. U.S.A. to grant exclusive perpetual license for two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), in exchange for an 82.2% equity stake in Kaveri.
Read more →📎 1 attachment
BSECompany UpdateFundraise22 Jun 2026
Lupin Ltd
Intimation regarding Grant of 1567591 Stock Option under Lupin Employees Stock Option Scheme 2025.
Lupin Ltd's Nomination and Remuneration Committee granted 1,567,591 stock options under its Employees Stock Option Scheme 2025. The options have an exercise price of ₹2.00 per share and will vest over three years in equal annual installments after the first year, subject to performance conditions. Grantees can exercise vested options within eight years from the effective grant date of July 1, 2026. This initiative is a standard practice for employee retention and motivation.
Read more →📎 1 attachment
← PreviousPage 2 of 2